Early and sustained deep molecular response achieved with nilotinib in high Sokal risk chronic myeloid leukemia patients

BACKGROUND: Nilotinib (Tasigna®) is a second-generation tyrosine kinase inhibitor that shows faster and deeper molecular responses (MR) in comparison to Imatinib as initial therapy in chronic phase chronic myeloid leukemia (CML). Efficacy and safety data for nilotinib in the Asian population is scar...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Manag Res
Autors principals: Zaidi, Uzma, Kaleem, Bushra, Borhany, Munira, Maqsood, Sidra, Fatima, Naveena, Sufaida, Gul, Ansari, Saqib Hussain, Farzana, Tasneem, Shamsi, Tahir Sultan
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2019
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6388993/
https://ncbi.nlm.nih.gov/pubmed/30863159
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S181911
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars